MRVI
Research Snapshot
Static fundamentals, valuation context, and investor signals for Maravai LifeSciences Holdings, Inc. (MRVI).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
-25.9%
ROIC, -38.1% FCF margin
Growth
-8.1%
5Y sales (revenue) CAGR
Balance sheet
1.4x
Debt/equity, 6.6x current ratio
Superinvestors
1
Top: First Eagle Investment Management (0.0%)
Strengths to research
- 8 annual periods are available for trend analysis.
Watchouts
- Free cash flow margin is negative at -38.1%.
- Five-year revenue trend is negative at -8.1%.
- Valuation multiples are limited or unavailable.
Annual data: 8 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for MRVI.
Grade F
5
/ 100
Financial Charts
No financial data available for MRVI (annual).
1 superinvestors own MRVI
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| First Eagle Investment Management First Eagle Investment Management | 2,524,336 | $7M | 0.01% | 0.0% |